Silexion Therapeutics (NASDAQ:SLXN) Shares Up 46.5% – Here’s What Happened

Silexion Therapeutics Corp (NASDAQ:SLXN) shares rose 46.5% during trading on Wednesday . The company traded as high as $1.29 and last traded at $1.03. Approximately 66,915,194 shares traded hands during mid-day trading, an increase of 1,052% from the average daily volume of 5,808,232 shares. The stock had previously closed at $0.70.

Analyst Upgrades and Downgrades

Separately, Maxim Group cut their target price on Silexion Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, March 20th.

Silexion Therapeutics Price Performance

The firm’s fifty day moving average is $1.03 and its 200-day moving average is $1.85.

Hedge Funds Weigh In On Silexion Therapeutics

An institutional investor recently bought a new position in Silexion Therapeutics stock. Meyer Handelman Co. acquired a new stake in Silexion Therapeutics Corp (NASDAQ:SLXN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 32,967 shares of the company’s stock, valued at approximately $36,000. Meyer Handelman Co. owned 0.39% of Silexion Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 10.95% of the company’s stock.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.